Abstract

Cancer is a complex disease characterized by a loss in the normal cell regulatory mechanisms that govern cell survival, proliferation, and differentiation. Current chemotherapeutics, as anticancer agents, are developing resistance to single drug and also to treatment therapies involving multiple drugs. Cross resistance associated with the specificity and selectivity of existing drugs has restricted the application of chemotherapy. Alternatively, these limitations have given better insight in understanding the underlying molecular mechanisms responsible for the development of various stages in cancer. In the light of this, continuous efforts are being made in order to identify and validate newer anticancer targets. This review presents some of the important targets that have been already reported, such as aromatase, farnesyl transferase, histone deacetylase, tyrosine kinase and cyclin-dependent kinase. A few molecules designed against these targets have successfully reached clinical trials. However, only limited marketed drugs are available from these classes. Besides, the review also highlights some of the other important targets and strategies that have also drawn considerable attention in the area of anticancer drug development such as, cancer stem cells and monoclonal antibodies. Further, the integration of the tools in molecular biology with the results from preclinical and clinical trials would strengthen the effectiveness of treatment regimens in cancer patients. There lies a much scope for designing promising lead compounds and treatment therapies against these established targets.

Original languageEnglish
Pages (from-to)489-507
Number of pages19
JournalIndian Journal of Experimental Biology
Volume53
Issue number8
Publication statusPublished - 01-08-2015

Fingerprint

Research
Pharmaceutical Preparations
Clinical Trials
Neoplasms
Histone Deacetylases
Aromatase
Neoplastic Stem Cells
Cyclin-Dependent Kinases
Therapeutics
Transferases
Antineoplastic Agents
Protein-Tyrosine Kinases
Molecular Biology
Cell Differentiation
Cell Survival
Monoclonal Antibodies
Cell Proliferation
Drug Therapy
Lead

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Medicine(all)
  • Molecular Biology
  • Cell Biology

Cite this

Jayashree, B. S. ; Nigam, Sukriti ; Pai, Aravinda ; Patel, Harsh K. ; Reddy, N. D. ; Kumar, Nitesh ; Rao, C. M. / Targets in anticancer research-a review. In: Indian Journal of Experimental Biology. 2015 ; Vol. 53, No. 8. pp. 489-507.
@article{b7da9a9c30bb4c49a98d8f73467cb3a4,
title = "Targets in anticancer research-a review",
abstract = "Cancer is a complex disease characterized by a loss in the normal cell regulatory mechanisms that govern cell survival, proliferation, and differentiation. Current chemotherapeutics, as anticancer agents, are developing resistance to single drug and also to treatment therapies involving multiple drugs. Cross resistance associated with the specificity and selectivity of existing drugs has restricted the application of chemotherapy. Alternatively, these limitations have given better insight in understanding the underlying molecular mechanisms responsible for the development of various stages in cancer. In the light of this, continuous efforts are being made in order to identify and validate newer anticancer targets. This review presents some of the important targets that have been already reported, such as aromatase, farnesyl transferase, histone deacetylase, tyrosine kinase and cyclin-dependent kinase. A few molecules designed against these targets have successfully reached clinical trials. However, only limited marketed drugs are available from these classes. Besides, the review also highlights some of the other important targets and strategies that have also drawn considerable attention in the area of anticancer drug development such as, cancer stem cells and monoclonal antibodies. Further, the integration of the tools in molecular biology with the results from preclinical and clinical trials would strengthen the effectiveness of treatment regimens in cancer patients. There lies a much scope for designing promising lead compounds and treatment therapies against these established targets.",
author = "Jayashree, {B. S.} and Sukriti Nigam and Aravinda Pai and Patel, {Harsh K.} and Reddy, {N. D.} and Nitesh Kumar and Rao, {C. M.}",
year = "2015",
month = "8",
day = "1",
language = "English",
volume = "53",
pages = "489--507",
journal = "Journal of scientific & industrial research. C. Biological sciences",
issn = "0019-5189",
publisher = "National Institute of Science Communication",
number = "8",

}

Targets in anticancer research-a review. / Jayashree, B. S.; Nigam, Sukriti; Pai, Aravinda; Patel, Harsh K.; Reddy, N. D.; Kumar, Nitesh; Rao, C. M.

In: Indian Journal of Experimental Biology, Vol. 53, No. 8, 01.08.2015, p. 489-507.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targets in anticancer research-a review

AU - Jayashree, B. S.

AU - Nigam, Sukriti

AU - Pai, Aravinda

AU - Patel, Harsh K.

AU - Reddy, N. D.

AU - Kumar, Nitesh

AU - Rao, C. M.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Cancer is a complex disease characterized by a loss in the normal cell regulatory mechanisms that govern cell survival, proliferation, and differentiation. Current chemotherapeutics, as anticancer agents, are developing resistance to single drug and also to treatment therapies involving multiple drugs. Cross resistance associated with the specificity and selectivity of existing drugs has restricted the application of chemotherapy. Alternatively, these limitations have given better insight in understanding the underlying molecular mechanisms responsible for the development of various stages in cancer. In the light of this, continuous efforts are being made in order to identify and validate newer anticancer targets. This review presents some of the important targets that have been already reported, such as aromatase, farnesyl transferase, histone deacetylase, tyrosine kinase and cyclin-dependent kinase. A few molecules designed against these targets have successfully reached clinical trials. However, only limited marketed drugs are available from these classes. Besides, the review also highlights some of the other important targets and strategies that have also drawn considerable attention in the area of anticancer drug development such as, cancer stem cells and monoclonal antibodies. Further, the integration of the tools in molecular biology with the results from preclinical and clinical trials would strengthen the effectiveness of treatment regimens in cancer patients. There lies a much scope for designing promising lead compounds and treatment therapies against these established targets.

AB - Cancer is a complex disease characterized by a loss in the normal cell regulatory mechanisms that govern cell survival, proliferation, and differentiation. Current chemotherapeutics, as anticancer agents, are developing resistance to single drug and also to treatment therapies involving multiple drugs. Cross resistance associated with the specificity and selectivity of existing drugs has restricted the application of chemotherapy. Alternatively, these limitations have given better insight in understanding the underlying molecular mechanisms responsible for the development of various stages in cancer. In the light of this, continuous efforts are being made in order to identify and validate newer anticancer targets. This review presents some of the important targets that have been already reported, such as aromatase, farnesyl transferase, histone deacetylase, tyrosine kinase and cyclin-dependent kinase. A few molecules designed against these targets have successfully reached clinical trials. However, only limited marketed drugs are available from these classes. Besides, the review also highlights some of the other important targets and strategies that have also drawn considerable attention in the area of anticancer drug development such as, cancer stem cells and monoclonal antibodies. Further, the integration of the tools in molecular biology with the results from preclinical and clinical trials would strengthen the effectiveness of treatment regimens in cancer patients. There lies a much scope for designing promising lead compounds and treatment therapies against these established targets.

UR - http://www.scopus.com/inward/record.url?scp=84938569656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938569656&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 489

EP - 507

JO - Journal of scientific & industrial research. C. Biological sciences

JF - Journal of scientific & industrial research. C. Biological sciences

SN - 0019-5189

IS - 8

ER -